KATELYN KLEMAIER: Open Payments
NPI 1588405625 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 39 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $970
Food & beverage: $970
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 5 | $124 |
| CATALYST PHARMACEUTICALS, INC. | 3 | $96 |
| JAZZ PHARMACEUTICALS INC. | 3 | $88 |
| SK Life Science, Inc. | 3 | $84 |
| HARMONY BIOSCIENCES LLC | 2 | $65 |
| ABBVIE INC. | 3 | $64 |
| Lundbeck LLC | 2 | $58 |
| GENZYME CORPORATION | 2 | $54 |
| Celgene Corporation | 2 | $48 |
| Genentech USA, Inc. | 2 | $47 |
Products named: Nayzilam, FYCOMPA, WAKIX, EPIDIOLEX, VYEPTI, QULIPTA, ZEPOSIA, Ocrevus.
Industry payments across IN — which companies pay providers there.
